source
- Biopharma must incentivize scientists to make early go-no-go decisionsThe article argues that simply urging scientists to think like entrepreneurs is not enough; biopharma firms need to align rewards with that mindset. Because only about one in ten drug candidates t…
- Biopharma needs to reward scientists' judgmentIt’s not enough for organizations to want scientists to think like entrepreneurs. They have to incentivize and reward for that behavior.BioSpace · 22d ago↗ source
- FDA approves Egetis’ Emcitate for rare genetic disease as Novo secures Chinese weight-loss pill in $2.6 billion dealThe U.S. Food and Drug Administration has granted approval to Egetis' Emcitate, a therapy targeting a rare genetic disorder. This marks a regulatory milestone for the company and patients awaiting…